Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Stacy

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Journal of Neural Transmission (Vienna, Austria : 1996)|June 22, 2010
The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's diseaseMark Stacy
Drugs & Aging|October 23, 2002
Sleep disorders in Parkinson's disease: epidemiology and managementMark Stacy
The International Journal of Neuroscience|November 1, 2011
Nonmotor symptoms in Parkinson's diseaseMark Stacy
Neurology|March 24, 2004
Apomorphine: North American clinical experienceMark Stacy
F1000 Medicine Reports|October 16, 2010
Impulse control disorders in Parkinson's diseaseMark Stacy
Neurologic Clinics|June 27, 2009
Medical treatment of Parkinson diseaseMark Stacy
Expert Opinion on Pharmacotherapy|August 19, 2007
Apomorphine in the treatment of Parkinson's diseaseRukmini Menon, Mark Stacy
Current Neurology and Neuroscience Reports|May 16, 2012
Adenosine A2A antagonists in Parkinson's disease: what's next?Patrick Hickey, Mark Stacy
Neurology|March 24, 2004
Other formulations and future considerations for apomorphine for subcutaneous injection therapyWilliam Koller, Mark Stacy
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
Respiratory complications of Parkinson's diseaseHolly Shill, Mark Stacy
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Journal of Neural Transmission (Vienna, Austria : 1996)|June 22, 2010
The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's diseaseMark Stacy
Drugs & Aging|October 23, 2002
Sleep disorders in Parkinson's disease: epidemiology and managementMark Stacy
The International Journal of Neuroscience|November 1, 2011
Nonmotor symptoms in Parkinson's diseaseMark Stacy
Neurology|March 24, 2004
Apomorphine: North American clinical experienceMark Stacy
F1000 Medicine Reports|October 16, 2010
Impulse control disorders in Parkinson's diseaseMark Stacy
Neurologic Clinics|June 27, 2009
Medical treatment of Parkinson diseaseMark Stacy
Expert Opinion on Pharmacotherapy|August 19, 2007
Apomorphine in the treatment of Parkinson's diseaseRukmini Menon, Mark Stacy
Current Neurology and Neuroscience Reports|May 16, 2012
Adenosine A2A antagonists in Parkinson's disease: what's next?Patrick Hickey, Mark Stacy
Neurology|March 24, 2004
Other formulations and future considerations for apomorphine for subcutaneous injection therapyWilliam Koller, Mark Stacy
Seminars in Respiratory and Critical Care Medicine|August 10, 2005
Respiratory complications of Parkinson's diseaseHolly Shill, Mark Stacy
Pageof 7